

AD _____

GRANT NO: DAMD17-94-J-4376


TITLE: "Positron Emitter I124 Iododeoxyuridine as a Tracer to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer"

PRINCIPAL INVESTIGATOR(S): Teresa Ann Gilewski, M.D.

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for
Cancer Research
New York, New York 10021

REPORT DATE: September 1995

TYPE OF REPORT: Annual



PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19951115 207

DTIC QUALITY INSPECTED 5

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

| | | | | |
|---|---|--|---|--|
| 1. AGENCY USE ONLY (Leave blank) | | 2. REPORT DATE September 1995 | 3. REPORT TYPE AND DATES COVERED Annual 1 Sep 94 - 31 Aug 95 | |
| 4. TITLE AND SUBTITLE Positron Emitter I124 Iododeoxyuridine as a Tracer to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer | | | 5. FUNDING NUMBERS DAMD17-94-J-4376 | |
| 6. AUTHOR(S) Teresa Ann Gilewski, M.D. | | | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Sloan-Kettering Institute for Cancer Research New York, New York 10021 | | | 8. PERFORMING ORGANIZATION REPORT NUMBER | |
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 | | | 10. SPONSORING/MONITORING AGENCY REPORT NUMBER | |
| 11. SUPPLEMENTARY NOTES | | | | |
| 12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited | | | 12b. DISTRIBUTION CODE | |
| 13. ABSTRACT (Maximum 200 words) | | | | |
| 14. SUBJECT TERMS Positron Emission Tomography, I124 Iododeoxyuridine, Advanced Breast Cancer, DNA Metabolism, Response, Humans, Clinical Trials, Anatomical Samples | | | 15. NUMBER OF PAGES 5 | |
| | | | 16. PRICE CODE | |
| 17. SECURITY CLASSIFICATION OF REPORT Unclassified | 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified | 20. LIMITATION OF ABSTRACT Unlimited | |

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet optical scanning requirements.

Block 1. Agency Use Only (Leave blank).

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

| | |
|----------------------|------------------------------|
| C - Contract | PR - Project |
| G - Grant | TA - Task |
| PE - Program Element | WU - Work Unit Accession No. |

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement.

Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

Block 13. Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code (*NTIS only*).

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories. ...

PI - Signature

Date

SUMMARY

Grant # DMAD 17-94-J-4376

"Positron emitter I¹²⁴ iododeoxyuridine as a tracer to follow DNA metabolism on scans and in tumor samples in advanced breast cancer."

The objectives of this study are: (1) to determine whether the biologic activity of locally advanced Stage III breast cancer as measured by ¹²⁴I-iododeoxyuridine (IUdR) uptake on positron emission tomography (PET) scans pre and post chemotherapy can be correlated with the clinical response as determined by physical examination and conventional radiographic studies, (2) to demonstrate that incorporation of IUdR is into the DNA contained within the tumor and that it correlates with the subsequent tumor response and proliferative activity of the tumor, (3) to further assess the biologic activity of tumor sites and clinical response by using a program which fuses PET scan images on computed tomography (CT) scans, magnetic resonance imaging (MRI) or SPECT bone scans.

Patients with Stage III breast cancer will have a complete extent of disease evaluation including routine radiographic studies. A PET scan with IUdR will be obtained within 2 weeks prior to therapy and after 4 cycles of chemotherapy. Whole body emission scans will be performed 24 hours after intravenous injection of 8 mCi of IUdR. Tumor biopsies will be obtained on the day of the PET scan and assessed for incorporation of IRdR into DNA. Flow cytometry and Ki-67 stains will also be obtained. Fusion imaging will generate resliced PET images that correspond to appropriate original CT, MRI or SPECT bone scan images.

There has been an unforeseen delay in the construction of the site for the positron emission tomography (PET) scan. It is expected that the PET scan will be operational in November 1995.

| | |
|--------------------|--|
| Accession For | |
| NTIS GRA&I | <input checked="checked" type="checkbox"/> |
| DTIC TAB | <input type="checkbox"/> |
| Unannounced | <input type="checkbox"/> |
| Justification | |
| By | |
| Distribution | |
| Availability Codes | |
| Dist | Avail and/or Special |
| A-1 | |